Blisibimod

( DrugBank: Blisibimod / KEGG DRUG: Blisibimod )


5 diseases
IDDisease name (Link within this page)Number of trials
43Microscopic polyangiitis1
44Wegener granulomatosis1
49Systemic lupus erythematosus3
IDDisease name (Link within this page)Number of trials
63Idiopathic thrombocytopenic purpura1
66IgA nephropathy8

43. Microscopic polyangiitis


Clinical trials : 95Drugs : 65 - (DrugBank : 23) / Drug target genes : 14 - Drug target pathways : 87 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

44. Wegener granulomatosis


Clinical trials : 122Drugs : 89 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 81 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

49. Systemic lupus erythematosus


Clinical trials : 1,227Drugs : 752 - (DrugBank : 175) / Drug target genes : 130 - Drug target pathways : 207 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 575Drugs : 261 - (DrugBank : 64) / Drug target genes : 61 - Drug target pathways : 142 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

66. IgA nephropathy


Clinical trials : 349Drugs : 251 - (DrugBank : 75) / Drug target genes : 43 - Drug target pathways : 152 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries